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Visual observation is a powerful approach for
screening bioactive compounds that can facilitate
the discovery of attractive druggable targets
following their chemicobiological validation. So far,
many high-content approaches, using sophisticated
imaging technology and bioinformatics, have been
developed. In our study, we aimed to develop
a simpler method that focuses on intact cell images
because we found that dynamic changes in mor-
phology are informative, often reflecting the mecha-
nism of action of a drug. Here, we constructed
a chemical-genetic phenotype profiling system,
based on the high-content cell morphology database
Morphobase. This database compiles the pheno-
types of cancer cell lines that are induced by
hundreds of reference compounds, wherein those
of well-characterized anticancer drugs are classified
by mode of action. Furthermore, we demonstrate the
applicability of this system in identifying NPD6689,
NPD8617, and NPD8969 as tubulin inhibitors.
INTRODUCTION
With the completion of the sequencing of the human genome
and the demonstration of dramatic clinical efficacy for emerging
molecular-target drugs, particularly imatinib, the trend in anti-
cancer drug discovery has shifted to a molecular target-based
approach. Whereas target-based screenings are believed to
be the most rational and powerful, classical phenotype screen-
ings, such asmorphology-based assay, have been reconsidered
and reintroduced as a complementary strategy for drug
discovery, especially in the exploration of first-in-class therapeu-
tics. For instance, certain benzoquinone ansamycins, such as
herbimycin and geldanamycin, were found to revert tyrosine
kinase-dependent oncogenic transformation (Uehara et al.,
1986), the molecular target of which Whitesell et al. (1994) iden-
tified as HSP90. Similarly, lactacystin, discovered as an inducer
of differentiation in Neuro2A cells, was demonstrated to target
the 20S proteasome, indicating that proteasome inhibitors1620 Chemistry & Biology 19, 1620–1630, December 21, 2012 ª2012generally have selective anticancer activity (Fenteany et al.,
1995; Omura et al., 1991).
Accordingly, phenotype-based screens are yet recognized as
a newmethod of drug discovery, and newly modified phenotypic
screens such as high-throughput, high-content imaging-driven,
and omics-based screens have been developed as the initial
step in the discovery of small molecule probes and drugs
(Feng et al., 2009; Houle et al., 2010; Roti and Stegmaier,
2012). With this renewed interest in phenotype screens,
however, the deduction of a molecular target of putative hits still
remains the rate-limiting stage, despite the significant techno-
logical advances in chemical biology. The success rate of iden-
tifying a compound with a specific mechanism of action and its
efficacy depends on our ability to compile and analyze the
knowledge of the possible molecular targets related to pheno-
types. In this regard, a multidimensional cell-based phenotype
profiling approach that is supported by genetic modification,
e.g., genome-wide gene depletion (genetics) or the application
of well-validated chemotherapeutics (chemical genetics), can
offer a promising strategy for discovering newdrugs and defining
their mechanisms of action. This strategy has allowed us and
other groups to establish such profiling systems and report
many important findings in recent years. For example, Perlman
et al. (2004) presented a high-throughput cytological profiling
method, in which the effects of 100 compounds were examined
at 13 3-fold dilution of each drug on various cellular components
in HeLa cells. To assess the similarity of compounds, they inte-
grated a titration-invariant similarity score to succeed in
grouping compounds with similarly reported targets and classi-
fying a poorly characterized austocystin to transcription and
translation inhibitors (Perlman et al., 2004). The CalMorph
system, developed by Ohya and colleagues, which compiled
comprehensive yeast cell morphological profiles of 4,718 nones-
sential gene deletion mutants, deduced the cellular functions of
well-characterized drugs by comparing the morphological
changes that were induced by gene deletion and versus the
test compound (Ohnuki et al., 2010). Abassi et al. (2009) devel-
oped a cell-based kinetic profiling approach using impedance
readout to monitor the effects of approximately 260 small mole-
cules. This approach has been used to analyze the calcium-
modulating activity of celecoxib, a Cox2 inhibitor, and identify
an additional mechanism (calcium channel inhibitory activity)
for the Eg5 inhibitor, monastrol (Abassi et al., 2009). Similarly,Elsevier Ltd All rights reserved
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complementation assays to measure changes in protein com-
plexes in response to 107 drugs, characterizing the off-target
effects and hidden phenotypes of certain drugs (MacDonald
et al., 2006). Recently, we reported a proteome-based profiling
system to predict the mechanism of action and molecular target
of a compound of interest (Muroi et al., 2010) and demonstrated
that BNS22 targets the catalytic domain of DNA topoisomerase II
(TOP2). This new type of TOP2 inhibitor is an attractive chemo-
therapeutic agent as an alternative to topoisomerase poisons
such as etoposide (Kawatani et al., 2011).
Even so, a primary screening is merely the starting point, and
one must challenge how to exploit unique bioactive substances
from a huge library rapidly and simply. To this end, we propose
chemical-genetic cell morphological profiling as a promising
method. The characteristic changes in morphology on exposure
to an agent are often associated with its mechanism of action.
Moreover, our data indicate that intact morphological changes
alone—without excessive immunological or fluorescent stain-
ing—are sufficient to profile drug responses (Osada et al.,
1988, 1997). In this study, using two cancer cell lines, we con-
structed an encyclopedia of cellular morphology, Morphobase,
consisting of the cell shape changes induced by various
compounds. Specifically, we developed a high-content image
analysis method to examine the effects of approximately 200
routinely used chemicals on morphology, accompanied by
statistical characterization of the obtained phenotypic data.
The importance of this database was verified by its identification
of the mechanism of action of three candidate drugs, comparing
the similarity in morphological features by test compounds and
those in the training data set. The Morphobase strategy not
only reproduces ‘‘drug-target-phenotype’’ relationships for
drugs with known targets, it also predicts unreported mecha-
nisms of action and facilitates the discovery of novel drug
candidates.
RESULTS
Tumor Cells Undergo Dynamic Changes Related
to the Mode of Action of a Drug
To construct the cell morphology database, we examined the
effects of roughly 30 well-characterized drugs on cell shape in
two mammalian cell lines—the human cervix epidermoid carci-
noma cell line HeLa and rat kidney cells that were infected with
ts25, a T class mutant of Rous sarcoma virus Prague strain,
srcts-NRK cells—over time and by dose. As summarized in
Figures 1 and S1A (available online), the cells that were exposed
to an agent underwent typical morphological changes, which
were similar between compounds of a pharmacological class.
For instance, protein synthesis inhibitors, such as reveromycin
A, cycloheximide, and anisomycin, induced the reversion of
the spherical shape of transformed srcts-NRK cells to a flattened
shape, characteristic of normal cells (Takahashi et al., 1992). The
morphological changes in srcts-NRK cells were classified
roughly into three categories—(1) flattened, (2) polygonal, and
(3) rounded—and subgrouped by variation in size and the pres-
ence of unique granular structures, spikes, and vacuoles (Fig-
ure S1B). In contrast, the morphological changes in HeLa cells
were less complicated, falling into three broad classes: (1)Chemistry & Biology 19, 1620–163flattened, (2) round up, and (3) toxic/growth inhibition, which
usually reflect stages in the cell cycle (G1/S phase, flattened
with embossed nucleus; G2/M, round up). These preliminary
observations indicated that the data on one cell line were not
sufficient to characterize each therapeutic group of anticancer
agents. However, the phenotypic response data of two or
more distinct cell lines can discriminate features that are related
to the mechanism of action of a particular compound.
High-Content Image Analysis of Subtle and Complex
Changes in Morphology
To eliminate unintentional human errors during visual inspection,
we recordedmorphological changes using an automatic system,
the IN Cell Analyzer, to perform a high-content image analysis.
This system can automatically recognize cytoskeletal mor-
phology and subcellular components and systematically
generate quantitative morphological data.
To manage the vast variety of phenotypes that are induced by
mechanistically distinct compounds, a custom-made image
analysis algorithm was designed using IN Cell Developer
Toolbox (GE Healthcare). On the first attempt, bright-field cell
images were collected by the IN Cell Analyzer, but it appeared
to be difficult to define every single cell accurately. Thus, nuclear
staining with Hoechst 33342 was introduced to define the
boundary between the cells and background. The unique
textures that were induced by a drug on the cell surface or inside
the cell were defined by the descriptor termed ‘‘Granular’’ for the
segmentation of these components (see Figure 2A and Experi-
mental Procedures for detailed segmentation algorithm). Using
this method, various types of morphological changes in srcts-
NRK and HeLa cells that were induced by small molecules—
the sizes and shapes, either of single cell or even tightly packed
cells—could be successfully segmented from one another, con-
firming that this general cellular segmentation algorithm can
monitor complex phenotypic responses in relevant cancer cell
types (Figure 2B). Figure 2C shows the flowchart of image pro-
cessing and measurements of morphological parameters for
the next data mining step. Once the bright-field and Hoechst
images of srcts-NRK or HeLa cells that were exposed to various
drugs were acquired, the ‘‘Nuclear,’’ ‘‘Cell,’’ and ‘‘Granular’’ frag-
ments were properly segmented, and 12 morphological param-
eters were output automatically.
Statistical Analysis of Multiparametric Phenotype Data
and Classification by Mode of Action
A test set of 207 authentic compounds, supplied by the RIKEN
Natural Products Depository (NPDepo) (http://www.npd.riken.
jp/npd) and SCADS inhibitor kits, was created (Table S1). Of
these compounds, 54 were drugs with well-characterized mech-
anisms of action, 118 were commonly used experimental drugs,
26 were FDA-approved drugs, 7 were reported to have multiple
biological targets, and 2 were antibiotics. To standardize the
conditions for monitoring the resulting morphological changes,
the following growth inhibitory concentrations were used:
IC85–95 values for HeLa cells and IC50–60 for src
ts-NRK cells,
calculated after a 48 hr exposure. The corresponding data are
shown in Table S1. For compounds with low cytotoxicity,
a maximum concentration of 25 mM was chosen for the expo-
sure. Following incubation, cells were fixed and stained with0, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1621
Figure 1. A Variety of Cell Shape Changes in srcts-NRK Cells Induced by Well-Characterized Drugs Classified by Mode of Action
srcts-NRK and HeLa cells were treated with well-characterized drugs at various concentrations and times. Representative images are shown of morphological
changes of srcts-NRK cells and HeLa cells observed under a microscope at 48 and 24 hr after treatment of a drug marked by an asterisk (*). Scale bars, 100 mm.
See also Figure S1.
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images of up to 1,500 cells from each well were collected and
analyzed using the image segmentation procedures above. A
set of descriptors, such as ‘‘Nuclear,’’ ‘‘Cell,’’ and ‘‘Granule,’’
was applied to each cell. To characterize ‘‘well-level’’ responses,
each parametric measurement was averaged, and the median
and SD were calculated to account for bi- or polyphasic pheno-
type responses, such as a mixture of large and small cells
(Figure 3). In total, 71 parameters were identified from 24
descriptors, yielding 14,697 data points (71 parameters 3 207
compounds).
To analyze this amount of multiparametric data, we developed
a data analysis program that incorporates multivariate statistical
tools to automatically analyze, visualize, and rank multiparamet-1622 Chemistry & Biology 19, 1620–1630, December 21, 2012 ª2012ric high-content phenotype results. Principal component
analysis (PCA) was applied to visualize the multiparametric
phenotype responses, and morphological similarities were
defined using our original index, termed ‘‘probability scores’’
and Euclidean distance (Figure 3). Figure 4 shows the projection
of the samples’ PCA scores onto the first two principal compo-
nents, which explains approximately 50% of variation in the
data set. The black dots in the middle represent the group of
vehicle controls; other spots on the 2D scatterplots represent
individual compounds, and the points of well-characterized
drugs are colored by target based on the literature. As a result,
drugs that had similar activities formed a cluster: the drugs
with a similar effect were circled by the same dotted lines,
wherein specific phenotypic responses were shown as distinctElsevier Ltd All rights reserved
Figure 2. Flowchart of Image Processing and Quantification of Morphological Parameters
(A) Scheme of the image segmentation program. The input images of bright-field and the same Hoechst 33342-stained cells were used for ‘‘Nuclear,’’ ‘‘Cell,’’ and
‘‘Granular’’ segmentation. ‘‘Nuclear’’ (blue) was assigned a nuclear-stained image. ‘‘Cell’’ (red) segmentation was achieved by allocating ‘‘Cell center,’’ derived
from the inverted bright-field image and nuclear information. ‘‘Granular’’ (pink) was defined based on inverted and pseudofluorescence bright-field images.
(B) Representative examples of the broad spectrum of heterogenic phenotype captures induced by distinct compounds. Nuclear and Cell region are colored in
blue and red, respectively. The pink bullets show Granular structures, and the yellow lines show Cell center.
(C) Scheme of image processing and morphology parameter measurement. After srcts-NRK or HeLa cells were segmented, 12 morphological parameters
(P1–P12) were quantified for each cell.
See also Table S1.
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Morphology-Based Profiling for Drug Discoverydistributions in the scatterplots. For instance, when we ranked
the nearest neighbors to every tubulin-targeted compound by
similarity, as determined by Euclidean distance metrics, typical
microtubule inhibitors nearly always ranked in the top 20 (Fig-
ure 4; Table S2). Similarly, other inhibitors with typical modes
of action, such as macromolecular synthesis, HDAC, and HSP,
were also well classified (Table S2), suggesting that our high-
content system can be successful in profiling phenotypes by
drug function and in a copy mimicking the visual observation.
In this system, given that test compounds form a cluster with
certain reference drugs of the data set, they are likely to have
similar or identical cellular targets. We chose a well-character-
ized drug set, comprising 54 drugs with 14 molecular targets
(Table S1), to encompass common mechanisms of toxicity and
therapeutic actions against cancer cells. Then, we developedChemistry & Biology 19, 1620–163a training algorithm that determines which of the 14 target class
in the training set were plausible candidates for compounds of
interest by ‘‘probability scores,’’ the mean Z scores for a test
compound to the median point of each target class (see Exper-
imental Procedures).
We employed three bioactive compounds (rotenone, 3-ATA,
resveratrol) to evaluate our proposed method. Rotenone is
a specific inhibitor of mitochondrial complex I, and 3-ATA was
developed as a CDK4 kinase inhibitor in vitro (Kubo et al.,
1999). Resveratrol has multiple activities, such as antioxidant,
anti-inflammatory, and anticancer properties (Fre´mont, 2000).
These compounds were tested in a newly established cell
morphology system and primarily expressed two characteristics
(Figure 5A). The high-content image profiling suggested that
rotenone was significantly associated with the tubulin cluster0, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1623
Figure 3. Schematic of Data Processing and Data Mining Step
Statistical values (Average, Median, SD) of obtained morphological parameters for 1,000 drug N-treated srcts-NRK and HeLa cells were calculated and
normalized to the control average values as drug N-specific phenotypic multiparameters. Phenotypic multiparameters of 207 test compounds profiled by
multivariate statistical analysis are illustrated. Morphobase profiling results are visualized by PCA, and the similarities in morphological changes between
a compound of interest and reference compounds are defined using two statistical computations. See also Table S1.
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Morphology-Based Profiling for Drug Discovery(Scoretubulin = 1.03) and that 3-ATA and resveratrol were associ-
ated with the inhibitors of DNA synthesis (ScoreDNA = 1.56 and
0.92, respectively), based on probability scores (Figure 5B) and
the rank of the top 20 nearest neighbors (Table S3). Actually,
these compounds also induce other effects that are unrelated
to the primary targets. Rotenone is an effective mitotic agent
(Brinkley et al., 1974), 3-ATA affects DNA synthesis in an intact
cell system (Diccianni et al., 2004), and most recent literature
described that resveratrol acts as a TOP2 poison in cancer cells
(Leone et al., 2010). Morphobase mostly provided the respon-
sible target for the growth inhibition and deduced their reported
side effects in the aforementioned case, indicating that our1624 Chemistry & Biology 19, 1620–1630, December 21, 2012 ª2012profiling approach detects the targets of drug candidates and
determines their mechanisms of action.
Target Prediction of Compounds of Interest by
Morphobase Profiling
Through our phenotypic screening of a chemical library in
NPDepo, we identified several hundreds of compounds that in-
hibited the growth of the human promyelocytic leukemia cell
line HL-60. In particular, NPD6689, NPD8617, and NPD8969
were very potent, as evidenced by the nanomolar ranges of their
IC50 values (Table 1). By cell-cycle analysis of HeLa cells that
were exposed to NPD6689 for 24 hr, the population in G2/MElsevier Ltd All rights reserved
Figure 4. Overview of Morphobase Profiling
The user interface displays the results of principle component scores in a 2D
scatterplot. The well-defined clusters can be distinguished from others by their
mechanisms of action. It also displays the compound’s predicted mode of
action and its probability score: smaller scores reflect higher probabilities. It
next ranks the 20 nearest neighbors of a test compound based on the
Euclidean distance between the selected compound’s positions. ctrl, control;
syn, synthesis. See also Figures S5 and S6 and Tables S1 and S2.
Figure 5. Target Profiling of Rotenone, 3-ATA, and Resveratrol
by Using Morphobase
srcts-NRK and HeLa cells were treated with rotenone, 3-ATA, or resveratrol,
and the obtained phenotype multiparameters were subjected to Morphobase
analysis. Target prediction was carried out based on probability scores and
similarity ranks, determined by Euclidean distance metrics.
(A) PCA scores of rotenone, 3-ATA, and resveratrol were projected onto 2D
scatterplots of PC1 and PC2.
(B) Ranking of the likelymodes of action for these compounds among 14 target
classes in the training set is shown.
See also Table S3.
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Morphology-Based Profiling for Drug Discoveryphase increased by concentration (Figure S2). Similar results
were obtained with the other compounds, suggesting that these
active substances affect G2/M phase events.
To detail the mechanism of action of these compounds, we
performed Morphobase profiling. Following treatment with
NPD6689, NPD8617, and NPD8969 at the concentrations in
Table S1, nuclei were stained, and the resulting morphological
changes were quantified by IN Cell Analyzer. The obtained
phenotypic multiparameters were compared with the reference
data set and subjected to statistical analysis. On projecting the
samples’ PCA scores, the phenotypic responses of NPD6689,
NPD8617, and NPD8969 were similar to each other and formed
a cluster around tubulin inhibitors in the scatterplots (Figure 6A).
In addition, based on the similarity analysis, NPD6689 was pre-
dicted to perturb microtubule dynamics (Scoretubulin = 1.06),
and most of its 20 closest neighbors were typical microtubuleChemistry & Biology 19, 1620–163inhibitors (Figure 6B; Table S4). Similar results were obtained
for NPD8617 and NPD8969, indicating that the molecular target
of these compounds is the microtubule system.
To verify these predictions, the compounds were subjected to
proteome profiling. The proteomic variation of 296 spots that
matched on all gel images was quantified, and hierarchical
cluster analysis was performed as described (Muroi et al.,
2010). Consistent with the Morphobase profiling, they were
clustered with typical microtubule-targeting inhibitors and near
the TOP2 catalytic inhibitors, such as BNS22 and ICRF193
(Figure S3).
The mechanism of action with regard to the microtubule
system was confirmed by in vitro microtubule assembly assay.
All three compounds inhibited the polymerization of tubulin
dose dependently (Figures 6C and S4A). Furthermore, these
effects were visualized in intact cells by immunofluorescence.0, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1625
Table 1. Growth Inhibitory Effects of NPD6689, NPD8617, and




A549 1.7 0.4 1.1
HeLa 0.6 0.2 0.2
HL-60 1.7 0.2 1.6
HT1080 2.0 0.2 0.5
Jurkat 0.6 0.1 0.2
MG-63 0.9 0.2 0.5
Saos-2 2.7 0.3 2.1
srcts-NRK 4.1 0.7 0.7
See also Figure S2.
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effected microtubule depolymerization, causing short microtu-
bule fragments to scatter throughout the cytoplasm as vinblas-
tine treatment (Figures 6D and S4B). The effects that approxi-
mated those of TOP2 catalytic inhibitors were excluded due to
the lack of distorted spindles and the failure of chromosomal
alignment and segregation. These data suggest that NPD6689,
NPD8617, and NPD8969 inhibit microtubule integrity in cell-
free and cell-based systems.
DISCUSSION
The discovery of novel bioactive substances has become
routine; however, one must judge immediately if their activities
in a primary screening can be advanced to the drug develop-
ment stage. Thus, the approximate mode of action must be
determined to select the compounds that selectively attack
tumors, and the speed of identification will save time and avoid
unnecessary efforts from being made. It has been known that
experienced cell biologists can judge the presumed mechanism
of action of a test compound properly by the simple observation
of typical morphological changes in treated cells. So far, several
morphology-based assay systems, using mammalian cells,
filamentous fungi, and yeasts, have been developed, some of
which have successfully led to the discovery of unique drugs
and probes (Frost et al., 1995; Gunji et al., 1983). In addition,
the accumulated knowledge on phenotypic data can help us
avoid the same mistakes repeatedly. For instance, we have
developed an in-house phenotype evaluation system, using
K562 cells (Osada et al., 1988), HL-60 cells, SHSY-5Y cells,
tsFT210 cells (Osada et al., 1997), and srcts-NRK cells, which
was effectively utilized for the discovery of novel microbial
metabolites (Kakeya et al., 1995) and to discriminate typical
ones: PKC inhibitors, such as staurosporine and K252a (bleb-
bing in K562 cells); tumor promoters, such as teleocidins and
TPA (differentiation of HL-60 cells; Huberman and Callaham,
1979); and protein synthesis inhibitors (flat reversion of srcts-
NRK cells; Osada et al., 1991). However, such know-how is
just empirical—there is obvious lack of consensus on morpho-
logical changes, partly due to a skill shortage, interobserver
variability, and the differences of the cell lines and test
compounds between laboratories—which often leads to incon-1626 Chemistry & Biology 19, 1620–1630, December 21, 2012 ª2012clusive results and delays in the wide application of this
method.
While screening for a compound that reverts the morphology
of srcts-NRK cells, we observed that vinblastine induced
a notable phenotype (Figure 1). We also noticed that when
treated with other chemicals, these cells experienced an endless
variety of changes in shape, prompting us to record the pheno-
types of srcts-NRK cells that were induced by various
compounds and classify these changes by certain rules. As ex-
pected, the cytoskeletal modulators of tubulin and actin
dynamics induced characteristic morphological changes that
were associated with their respective targets. Notably, the other
drugs, such as inhibitors of macromolecule synthesis, HSP, or
HDAC inhibitors, whose effects are unrelated to the cytoskel-
eton, also induced the unique alternations in morphology. The
cross-validation of phenotypic responses between srcts-NRK
and HeLa cells has the following advantage: for either cell line,
it was difficult to recognize certain phenotypes, such as those
induced by HDAC and proteasome inhibitors in srcts-NRK cells
(flattened), and protein or RNA synthesis inhibitors in HeLa cells
(toxic/growth inhibition). However, with phenotype response
data for two distinct cell lines, we could discriminate them easily.
Another advantage is the increase in number of compounds that
can be analyzed; because drug sensitivity depends on cell types,
by using two different cell lines, we could validate the phenotype
of a drug that could not be visualized in either cell line in indi-
vidual assays. Finally, we could easily discern the 13 types of
phenotypes that were induced by typical anticancer drugs (Fig-
ure 1). Few studies have reported the systematic collection of the
morphological changes that are induced by drugs in intact
mammalian cells or their chemical-genetic classification (Sumiya
et al., 2011), due to the limited number of phenotypic changes
observed in the cells used. Our observations on the srcts-NRK
cell line revealed their potential to react to external signals with
a wide variety of the morphological changes, possibly because
it was transformed by oncogenic v-Src (Chen et al., 1977).
Compared with HeLa cells, the broad spectrum of Src activities
(Thomas and Brugge, 1997) might confer specific characteristics
in a highly developed cytoskeletal system, enhance survival in
a specific environment and against cytocidal drugs, or disrupt
inherent cell-cycle checkpoints. Thus, we expect the ability to
induce these changes to be coupled with many diverse classes
of cellular targets. Dozens of Src-interacting proteins have
been identified (Luo et al., 2008); however, the precious role of
Src and the impact of its modulators on morphology remain
unclear. Agents that induce unique shapes in srcts-NRK cells
are potentially useful drugs for cancer treatment or probes for
better understanding of Src function and its related signal
transduction.
In this report, we developed a high-content imagemethod and
a phenotype profiling system using a similarity search software,
based on a statistical analysis of multiparametric phenotype
responses, to identify the molecular targets of compounds of
interest with an ‘‘unbiased eye.’’ Unlike other methods (Pepper-
kok and Ellenberg, 2006), our system consists only of a 96-well
plate, a microscope, and general fluorescent nuclear staining.
Thus, this simple system allows us to select substances immedi-
ately without the pitfalls of fluorescence-based assays. Actually,
in Morphobase profiling, we can distinguish between the modesElsevier Ltd All rights reserved
Figure 6. Target Profiling of Three Antimitotics by Using Morphobase
srcts-NRK and HeLa cells were treated with NPD6689, NPD8617, or NPD8969, and the resulting phenotype multiparameters were subjected to Morphobase
analysis.
(A) PCA scores for NPD6689, NPD8617, and NPD8969 were projected onto a 2D scatterplot of PC1 and PC2.
(B) Ranking of the likely mode of action among 14 target classes in the training set is shown.
(C) Effect of NPD6689 on in vitro tubulin polymerization is presented.
(D) Effect of NPD6689 on microtubules in interphase and mitotic spindle morphology is demonstrated. Cells were treated with the indicated compounds for 12 hr
and stained with anti-a-tubulin (green), anti-g-tubulin (red), and DAPI (blue). Scale bars, 10 mm.
See also Figures S2–S5 and Table S4.
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etoposide (TOP2 poison), although they target the same protein,
as in proteome profiling. Intriguingly, proteasome and HSP90
inhibitors or TOP2 catalytic and tubulin inhibitors lay in overlap-
ping clusters by proteome profiling, but Morphobase profiling
discriminated them clearly. Nonetheless, Morphobase suffers
from a disadvantage in characterizing drugs that effect colorless
morphological change, such as certain kinase inhibitors. Thus,
an effective complementary combination of proteome and Mor-
phobase profiling should be required to identify the mechanism
of action more accurately.
Morphobase profiling provides us an exciting perspective for
the prediction of the side effects and ancillary mechanisms of
a drug. Recently, we focused on rotenone, 3-ATA, and resvera-
trol and identified their additional modes of action, consist with
previous reports: rotenone as a tubulin inhibitor (Brinkley et al.,
1974) and the latter two drugs as DNA synthesis inhibitors (Dic-
cianni et al., 2004; Leone et al., 2010). Further characterization of
the compounds that we examined in this study and those in
widespread clinical practice will increase our understanding
of their action mechanisms and side effects, advancing drug
discovery efforts. On the contrary, drug-induced phenotypesChemistry & Biology 19, 1620–163are often changed depending on its concentration, and Morpho-
base mostly provided the responsible target for its growth inhib-
itory activity. In our future study, the assessments in primary
screening will be carried out at single concentration in order
to select compounds of interest from huge samples as quick
as possible. Consequently, to speculate on a target, we will
examine candidates’ biological activities at multiple concentra-
tions at first and then we turn into the morphological profiles.
More recently, we have identified a biosynthetic gene cluster
for terpendole E and isolated several indole-alkaloid com-
pounds from the gene-engineered strain of Chaunopycnis alba
(Motoyama et al., 2012). Paspaline is a common key interme-
diate of the terpendole pathway and paxilline pathway. The
molecular target of paspaline isolated from the mutant strain of
C. alba is predicted to be Eg5 by Morphobase profiling (Figures
4 and S6A). Remarkably, the target can be predicted, even when
crude extracts of the mutant strain (PQ-2) were tested (Figures
S6B and 6C). These data verified the utility of our profiling system
to predict various pharmacological targets of mechanistically
unknown drugs and even crude natural products.
In conclusion, to discover small drug-likemolecules, we devel-
oped a cell phenotype profiling system using a morphology0, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1627
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Morphology-Based Profiling for Drug Discoverydatabase, Morphobase. Our system classifies the modes of
action of test compounds and predicts side and off-target
effects, leading us to identify NPD6689, NPD8617, and
NPD8969 as tubulin inhibitors. Currently, there are many cancer
therapeutics that alter microtubule dynamics, including vinca
alkaloids and taxanes. Tubulin is an old molecular target, but
it remains attractive, as demonstrated by the recent FDA
approval of eribulin for cancer treatment (Jain and Cigler,
2012). Although 6-furan-2-yl-3-methyl-4-oxo-4,5,6,7-tetrahy-
dro-1H-indole-2-carboxylic acid derivatives that have similar
chemical structures to NPD8969 have been reported as tubulin
inhibitors (Screpanti et al., 2010), others are structurally unre-
lated to existing antitubulin agents. In addition, these antimitotics
have antiproliferative activities against the vindesine- and pacli-
taxel-resistant H69 human small-cell lung cancer cell line (Fig-
ure S5), implicating it as a lead compound for the development
of a new class of antitubulin drugs that overcome clinically
evident drug resistance.
The Morphobase system rapidly groups a newly discovered
compound to a class with similar mechanisms of action. With
data on other cell lines, the exact molecular target can be pin-
pointed, based on the combination of morphological changes.
Knockdown of specific genes by RNAi might provide us with
exact morphological changes in the cells and improve the accu-
racy of the system in identifying the molecular mechanisms of
drug activity and toxicity as well.
SIGNIFICANCE
To discover small drug-like molecules, we established the
encyclopedic cell morphology database Morphobase, being
inspired by our findings that cells dynamically and specifi-
cally alter their morphology depending on the mode of
action of a drug. We examined the effects of approximately
200 well-characterized drugs on themorphological changes
of intact cells in two cancer cell lines. We also prepared a
custom-made image analysis algorithm to monitor cell
morphology in detail and transformed an analog cell
morphology database into an automated high-content data-
base in which the phenotypes and mechanism of action of a
drug are quantitatively linked in a chemical-genetic fashion.
Using this database, we can easily discriminate typical anti-
cancer drug-induced phenotypes and profile the side effects
of drugs with multiple biological targets, such as rotenone.
Moreover, in combination with statistic computations, we
identified tubulin as the molecular target of the mechanisti-
cally unknown drugs NPD6689, NPD8617, and NPD8969 and
demonstrated that these compounds inhibit microtubule
dynamics in vitro and in a cell-based system.
Overall, as an alternative to current high-content
approaches, we established a chemical-genetic phenotype
profiling system, based on Morphobase. Our system clas-
sifies the modes of action of well-characterized compounds
and predicts compounds with reported side (or off-target)
effects or with unknown mechanisms. This sensitive and
convenient profiling tool can determine the mechanisms of
action and off-target effects of drugs and will facilitate the
discovery of bioactive compounds with unknown mecha-
nisms of action.1628 Chemistry & Biology 19, 1620–1630, December 21, 2012 ª2012EXPERIMENTAL PROCEDURES
Compounds
Authentic compounds and the chemical library were provided by the RIKEN
NPDepo (Osada, 2010) and SCADS inhibitor kits (Kong et al., 2010). The
origins of all compounds used to construct Morphobase are summarized
in Table S1. The purity and structure of each hit compound were confirmed
by spectral analysis; only NPD6689, due to its low purity, was prepared by
chemical synthesis (see also Supplemental Experimental Procedures).
Cell Culture
srcts-NRK cells (Chen et al., 1977), rat kidney cells that were infected with ts25,
aTclassmutant ofRoussarcomavirusPraguestrain (gifted fromDr.Y.Uehara),
were cultured at permissive temperature (32C) in Eagle’s minimal essential
medium (EMEM; Sigma-Aldrich), supplemented with 10% calf serum (CS; Ni-
chirei). Thehumancervix epidermoidcarcinomacell lineHeLa, thehumanfibro-
sarcoma cell line HT1080, and the human lung adenocarcinoma cell line A549
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen),
supplemented with 10% fetal bovine serum (FBS, Nichirei). The human small-
cell lung cancer cell line H69, vindesine-resistant (H69/VDS) and paclitaxel-
resistant cell lines (H69/Txl) (gifted from Dr. F. Koizumi) (Yoshida et al., 2007),
the human promyelocytic leukemia cell line HL-60, and the human T lympho-
cyte cell line Jurkat were cultured in RPMI-1640 medium (Invitrogen), supple-
mentedwith 10%FBS. The human osteosarcoma cell lineMG-63was cultured
in EMEM, supplemented with 10% FBS. The human osteosarcoma cell line
Saos-2 was cultured in McCoy’s (Invitrogen), supplemented with 10% FBS.
All cell lines except for srcts-NRKandH69were obtained fromRIKENCell Bank.
Image Acquisition and Analysis
srcts-NRK cells (1 3 104 cells/well in 100 ml EMEM) and HeLa cells (4 3 103
cells/well in 100 ml DMEM) were plated on poly-D-lysin-coated, black,
96-well clear-bottom plates (Bio-One mclear; Greiner). After a 48 or 24 hr expo-
sure to a test compound for srcts-NRK or HeLa cells, respectively, the cells
were fixed by direct addition of 100 ml 7.4% formalin and 2 mg/ml Hoechst
33342 (Sigma-Aldrich) in PBS and were incubated for 1 hr at room tempera-
ture. Bright-field images and corresponding nuclear images were acquired
on an IN Cell Analyzer 2000 (GE Healthcare) using a 340 objective (NA
0.45), a 12-bit camera with 1 3 1 pixel binning, and a laser autofocus system
until 1,500 cells were analyzed in each well. Unanalyzable images—such as
those with a tiny scratch on the plates or floc—were removed, and the remain-
ing images, consisting of approximately 1,000 cells, were analyzed with
custom-designed image analysis algorithms that were created with IN Cell
Developer Toolbox as follows:
Step 1: ‘‘Nuclear’’ segmentation. Nuclear-stained images were segmented
using the objective segmentation module. Postprocessing nodes, such as
dilation, erosion, and sieve, were used to separate close nuclei and prop-
erly segment the diverse nuclear phenotypes.
Step 2: ‘‘Cell’’ segmentation. First, preprocessing (inversion of intensity of
bright-field images) and removal of tiny objects that were irrelevant to cell
shape were performed. Then, ‘‘Cell center’’ was predefined as a seed
region of cell contour using the objective segmentation module and
postprocessing nodes and allocating nuclei to respective cells. ‘‘Cell’’
was defined as the cellular regions that corresponded to ‘‘Cell center’’
by the objective segmentation module.
Step 3: Granular segmentation. The invert images above and pseudofluor-
escence images that were generated from bright-field images were used
to detect textures, such as granules and vesicles, which were recognized
by the vesicle segmentation module.
Step 4: Measure nodes. After individual cells were segmented, 12 user-
defined descriptors (nuclear area, nuclear perimeter, nuclear form factor,
nuclear major/minor axis length, nuclear count, nuclear intensity, cell
area, cell perimeter, cell major/minor axis length, cell form factor, granular
counts, and granular area) were calculated for each cell.
Statistical Analysis
Data Processing, Normalization, and PCA
To characterize well-level phenotypic responses, the average, median, and
SD of each parametric measurement were calculated. Because the medianElsevier Ltd All rights reserved
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parameters (12 parameters3 3 statistics3 2 cells 1 statistics) were normal-
ized to the average corresponding control values of the DMSO-treated cells;
common logarithmic outputs (xj) were then applied to the subsequent statis-
tical analysis. For PCA, The eigenvalue-eigenvector of the covariance matrix
was calculated, and the resulting principal component scores were displayed
in a 2D scatterplot.
Target Estimation by Morphobase Profiling
The prediction of a target molecule or mechanism of action of a test drug was
demonstrated by using two statistical computations:
(1) Probability scores. First, we calculated the coordinate of the median
point (ai = (ai1, ai2. ain)) and the SD (si = (si1, si2. sin)) for each well-
characterized ‘‘Targeti’’ as a training data set. To predict a compound’s












where xj is the coordinate of the test compound, and n is the number of
the parameter. If Scorei = 0, the compound lies at the median point of
Targeti. If probability Scorei = 1, it lies on the hyperplane that forms from
the median point and SD of Targeti: A smaller score reflects a greater
probability.
(2) The ranking of the nearest neighbors to a test compound. The similarity
is determined by Euclidean distance between selected compound and
reference compounds: smaller distance reflects closer phenotypic
readouts to the test compound. We can assign test compound to the
class to which most of its nearest neighbors belong.
In Vitro Tubulin Polymerization Assay
In vitro tubulin polymerization assay was performed using the Tubulin
Polymerization Assay Kit (Cytoskeleton) per the manufacturer’s instructions.
Briefly, lyophilized porcine tubulin was solubilized to a final concentration of
2 mg/ml in reaction buffer, containing 80 mM PIPES (pH 6.9), 2 mM MgCl2,
0.5 mM EGTA, 1 mM GTP, 10 mM fluorescent reporter, and 20% glycerol,
and kept at 4C. Compounds, (100 3 DMSO stock solutions) were added to
prewarmed half-area 96-well black plates. Cold tubulin solution was added
to the wells, the plate contents were mixed by shaking, and the absorbance
at 340 nm was read every minute for 1 hr.
Immunofluorescence Cell Staining
For a-tubulin and g-tubulin costaining, cells were fixed in ice-cold methanol for
5 min and washed with PBS. After being blocked with 0.5% BSA in PBS for
5min at room temperature, the slideswere incubated sequentially with primary
antibodies, each diluted 1:200 in PBS with 0.5% BSA, for 1 hr at 37C and
Alexa-conjugated secondary antibodies, each diluted 1:500 in PBS with
0.5% BSA, for 40 min at 37C. Cells were also counterstained with DAPI to
visualize the nuclei. Images were acquired on a fluorescence microscope
(PROVIS AX70; Olympus). The primary antibodies were mouse monoclonal
anti-a-tubulin and rabbit polyclonal anti-g-tubulin (Sigma-Aldrich); the
secondary antibodies were Alexa 488 goat anti-mouse IgG and Alexa 546
goat anti-rabbit IgG (Molecular Probes).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chembiol.2012.10.014.
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